13 results on '"Papadia, Sofia"'
Search Results
2. Neuronal activity controls the antagonistic balance between peroxisome proliferator-activated receptor-γ coactivator-1α and silencing mediator of retinoic acid and thyroid hormone receptors in regulating antioxidant defenses.
- Author
-
Soriano FX, Léveillé F, Papadia S, Bell KF, Puddifoot C, and Hardingham GE
- Subjects
- Animals, Neurons pathology, Nuclear Receptor Co-Repressor 2 genetics, Oxidative Stress, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, RNA-Binding Proteins genetics, Rats, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors genetics, p38 Mitogen-Activated Protein Kinases metabolism, Antioxidants metabolism, Neurons metabolism, Nuclear Receptor Co-Repressor 2 antagonists & inhibitors, Nuclear Receptor Co-Repressor 2 metabolism, RNA-Binding Proteins antagonists & inhibitors, RNA-Binding Proteins metabolism, Transcription Factors antagonists & inhibitors, Transcription Factors metabolism
- Abstract
Transcriptional coactivators and corepressors often have multiple targets and can have opposing actions on transcription and downstream physiological events. The coactivator peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α is under-expressed in Huntington's disease and is a regulator of antioxidant defenses and mitochondrial biogenesis. We show that in primary cortical neurons, expression of PGC-1α strongly promotes resistance to excitotoxic and oxidative stress in a cell autonomous manner, whereas knockdown increases sensitivity. In contrast, the transcriptional corepressor silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) specifically antagonizes PGC-1α-mediated antioxidant effects. The antagonistic balance between PGC-1α and SMRT is upset in favor of PGC-1α by synaptic activity. Synaptic activity triggers nuclear export of SMRT reliant on multiple regions of the protein. Concomitantly, synaptic activity post-translationally enhances the transactivating potential of PGC-1α in a p38-dependent manner, as well as upregulating cyclic-AMP response element binding protein-dependent PGC-1α transcription. Activity-dependent targeting of PGC-1α results in enhanced gene expression mediated by the thyroid hormone receptor, a prototypical transcription factor coactivated by PGC-1α and repressed by SMRT. As a consequence of these events, SMRT is unable to antagonize PGC-1α-mediated resistance to oxidative stress in synaptically active neurons. Thus, PGC-1α and SMRT are antagonistic regulators of neuronal vulnerability to oxidative stress. Further, this coactivator-corepressor antagonism is regulated by the activity status of the cell, with implications for neuronal viability.
- Published
- 2011
- Full Text
- View/download PDF
3. Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons.
- Author
-
Fricker M, Papadia S, Hardingham GE, and Tolkovsky AM
- Subjects
- Animals, Animals, Newborn, Apoptosis Regulatory Proteins genetics, Cerebral Cortex cytology, Mice, Mice, Knockout, Nerve Degeneration genetics, Nerve Degeneration physiopathology, Neurons physiology, Nuclear Proteins genetics, Signal Transduction genetics, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 physiology, Tumor Suppressor Proteins genetics, Apoptosis physiology, Apoptosis Regulatory Proteins physiology, Cerebral Cortex physiology, Nerve Degeneration metabolism, Neurons cytology, Nuclear Proteins physiology, Tumor Suppressor Proteins physiology
- Abstract
Puma (p53 up-regulated modulator of apoptosis) is a BH3-only protein member of the Bcl-2 family that controls apoptosis by regulating the release of pro-apoptotic factors from mitochondria. Previously, we reported that sodium arsenite (NaAsO(2)) induces Puma-dependent apoptosis in cortical neurons in a p53-independent manner. The following evidence shows that p53-independent Puma activation by NaAsO(2) is mediated by the p53-related protein TAp73: (i) NaAsO(2) causes TAp73alpha accumulation and increases p53-independent expression of p73 target genes; (ii) two p53 response elements in the Puma promoter are required for NaAsO(2)-mediated activation of a Puma reporter construct; (iii) expression of the inhibitory DeltaNp73alpha and DeltaNp73beta isoforms decreases NaAsO(2)-mediated induction of Puma and other p53-family target genes in a p53-null background; (iv) DeltaNp73alpha and DeltaNp73beta expression protects the neurons from NaAsO(2)-dependent apoptosis. Interestingly, although ER stressors also induce p53-independent, Puma-dependent apoptosis, they do not increase TAp73 expression while NaAsO(2) does not induce notable endoplasmic reticulum (ER) stress. In contrast, DNA damaging agents, okadaic acid, and H(2)O(2) all induce apoptosis in a strictly Puma- and p53-dependent manner. Hence, the pivotal position of Puma as mediator of apoptosis in cortical neurons is because of the availability of at least three independent signalling pathways that ensure its activation.
- Published
- 2010
- Full Text
- View/download PDF
4. Suppression of the intrinsic apoptosis pathway by synaptic activity.
- Author
-
Léveillé F, Papadia S, Fricker M, Bell KF, Soriano FX, Martel MA, Puddifoot C, Habel M, Wyllie DJ, Ikonomidou C, Tolkovsky AM, and Hardingham GE
- Subjects
- 4-Aminopyridine pharmacology, Analysis of Variance, Animals, Animals, Newborn, Apoptosis drug effects, Apoptosis Regulatory Proteins deficiency, Apoptosis Regulatory Proteins metabolism, Apoptotic Protease-Activating Factor 1 metabolism, Bicuculline pharmacology, Caspase 9 metabolism, Cells, Cultured, Cerebral Cortex cytology, Cytochromes c metabolism, Dizocilpine Maleate pharmacology, Dose-Response Relationship, Drug, Drug Combinations, Embryo, Mammalian, Enzyme Inhibitors pharmacology, GABA Antagonists pharmacology, Green Fluorescent Proteins genetics, Male, Mice, Mice, Inbred C57BL, Mutation genetics, Neural Inhibition drug effects, Neurons drug effects, Neuroprotective Agents pharmacology, Potassium Channel Blockers, Signal Transduction drug effects, Staurosporine pharmacology, Synapses drug effects, Tacrolimus analogs & derivatives, Tacrolimus pharmacology, Time Factors, Transfection methods, Tumor Suppressor Protein p53 deficiency, Tumor Suppressor Protein p53 metabolism, Tumor Suppressor Proteins deficiency, Tumor Suppressor Proteins metabolism, Up-Regulation drug effects, Apoptosis physiology, Neural Inhibition physiology, Neurons physiology, Signal Transduction physiology, Synapses physiology
- Abstract
Synaptic activity promotes resistance to diverse apoptotic insults, the mechanism behind which is incompletely understood. We show here that a coordinated downregulation of core components of the intrinsic apoptosis pathway by neuronal activity forms a key part of the underlying mechanism. Activity-dependent protection against apoptotic insults is associated with inhibition of cytochrome c release in most but not all neurons, indicative of anti-apoptotic signaling both upstream and downstream of this step. We find that enhanced firing activity suppresses expression of the proapoptotic BH3-only member gene Puma in a NMDA receptor-dependent, p53-independent manner. Puma expression is sufficient to induce cytochrome c loss and neuronal apoptosis. Puma deficiency protects neurons against apoptosis and also occludes the protective effect of synaptic activity, while blockade of physiological NMDA receptor activity in the developing mouse brain induces neuronal apoptosis that is preceded by upregulation of Puma. However, enhanced activity can also confer resistance to Puma-induced apoptosis, acting downstream of cytochrome c release. This mechanism is mediated by transcriptional suppression of apoptosome components Apaf-1 and procaspase-9, and limiting caspase-9 activity, since overexpression of procaspase-9 accelerates the rate of apoptosis in active neurons back to control levels. Synaptic activity does not exert further significant anti-apoptotic effects downstream of caspase-9 activation, since an inducible form of caspase-9 overrides the protective effect of synaptic activity, despite activity-induced transcriptional suppression of caspase-3. Thus, suppression of apoptotic gene expression may synergize with other activity-dependent events such as enhancement of antioxidant defenses to promote neuronal survival.
- Published
- 2010
- Full Text
- View/download PDF
5. Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione.
- Author
-
Soriano FX, Léveillé F, Papadia S, Higgins LG, Varley J, Baxter P, Hayes JD, and Hardingham GE
- Subjects
- Animals, Antioxidants pharmacology, Apoptosis drug effects, Cerebral Cortex cytology, Drug Interactions, Embryo, Mammalian, Enzyme Activation drug effects, Hydrogen Peroxide pharmacology, Hydroquinones pharmacology, Indoles, Mice, Mutation physiology, NF-E2-Related Factor 2 genetics, NF-E2-Related Factor 2 metabolism, Nerve Tissue Proteins metabolism, Neuroglia drug effects, Neuroglia metabolism, Oxidative Stress drug effects, Oxidoreductases metabolism, Peroxiredoxins genetics, RNA, Messenger metabolism, Rats, Transcription Factor AP-1 genetics, Transcription Factor AP-1 metabolism, Transfection methods, Neurons drug effects, Neurons metabolism, Peroxiredoxins metabolism, Thiones pharmacology, Thiophenes pharmacology, Up-Regulation drug effects
- Abstract
Peroxiredoxins are an important family of cysteine-based antioxidant enzymes that exert a neuroprotective effect in several models of neurodegeneration. However, under oxidative stress they are vulnerable to inactivation through hyperoxidation of their active site cysteine residues. We show that in cortical neurons, the chemopreventive inducer 3H-1,2-dithiole-3-thione (D3T), that activates the transcription factor Nuclear factor erythroid 2-related factor (Nrf2), inhibits the formation of inactivated, hyperoxidized peroxiredoxins following oxidative trauma, and protects neurons against oxidative stress. In both neurons and glia, Nrf2 expression and treatment with chemopreventive Nrf2 activators, including D3T and sulforaphane, up-regulates sulfiredoxin, an enzyme responsible for reducing hyperoxidized peroxiredoxins. Induction of sulfiredoxin expression is mediated by Nrf2, acting via a cis-acting antioxidant response element (ARE) in its promoter. The ARE element in Srxn1 contains an embedded activator protein-1 (AP-1) site which directs induction of Srxn1 by synaptic activity. Thus, raising Nrf2 activity in neurons prevents peroxiredoxin hyperoxidation and induces a new member of the ARE-gene family, whose enzymatic function of reducing hyperoxidized peroxiredoxins may contribute to the neuroprotective effects of Nrf2 activators.
- Published
- 2008
- Full Text
- View/download PDF
6. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability.
- Author
-
Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H, and Hardingham GE
- Subjects
- Action Potentials drug effects, Animals, Apoptosis drug effects, Apoptosis physiology, Cell Survival drug effects, Cell Survival physiology, Cells, Cultured, Dose-Response Relationship, Drug, Hippocampus drug effects, Hippocampus embryology, Neurons drug effects, Rats, Rats, Sprague-Dawley, Synaptic Transmission drug effects, Action Potentials physiology, Hippocampus physiology, N-Methylaspartate administration & dosage, Neurons physiology, Neuroprotective Agents administration & dosage, Receptors, N-Methyl-D-Aspartate metabolism, Synaptic Transmission physiology
- Abstract
Neuroprotection can be induced by low doses of NMDA, which activate both synaptic and extrasynaptic NMDA receptors. This is in apparent contradiction with our recent findings that extrasynaptic NMDA receptor signaling exerts a dominant inhibitory effect on prosurvival signaling from synaptic NMDA receptors. Here we report that exposure to low preconditioning doses of NMDA results in preferential activation of synaptic NMDA receptors because of a dramatic increase in action potential firing. Both acute and long-lasting phases of neuroprotection in the face of apoptotic or excitotoxic insults are dependent on this firing enhancement. Key mediators of synaptic NMDA receptor-dependent neuroprotection, phosphatidylinositol 3 kinase-Akt (PI3 kinase-Akt) signaling to Forkhead box subgroup O (FOXO) export and glycogen synthase kinase 3beta (GSK3beta) inhibition and cAMP response element-binding protein-dependent (CREB-dependent) activation of brain-derived neurotrophic factor (BDNF), can be induced only by low doses of NMDA via this action potential-dependent route. In contrast, NMDA doses on the other side of the toxicity threshold do not favor synaptic NMDA receptor activation because they strongly suppress firing rates below baseline. The classic bell-shaped curve depicting neuronal fate in response to NMDA dose can be viewed as the net effect of two antagonizing (synaptic vs extrasynaptic) curves: via increased firing the synaptic signaling dominates at low doses, whereas firing becomes suppressed and extrasynaptic signaling dominates as the toxicity threshold is crossed.
- Published
- 2006
- Full Text
- View/download PDF
7. Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection.
- Author
-
Papadia S, Stevenson P, Hardingham NR, Bading H, and Hardingham GE
- Subjects
- Animals, Animals, Newborn, Apoptosis drug effects, Apoptosis physiology, Bicuculline pharmacology, Blotting, Western methods, Calcium Signaling drug effects, Cell Nucleus drug effects, Ceramides pharmacology, Cyclic AMP Response Element-Binding Protein genetics, Dizocilpine Maleate pharmacology, Dose-Response Relationship, Drug, Drug Interactions, Enzyme Inhibitors pharmacology, Excitatory Amino Acid Antagonists pharmacology, GABA Agonists, GABA Antagonists pharmacology, Gene Expression drug effects, Gene Expression physiology, Green Fluorescent Proteins biosynthesis, Hippocampus, In Vitro Techniques, Muscimol pharmacology, Neurons drug effects, Neurons physiology, Neuroprotective Agents pharmacology, Oncogene Protein v-akt metabolism, Phosphatidylinositol 3-Kinases metabolism, Sodium Channel Blockers pharmacology, Tetrodotoxin pharmacology, Time Factors, Transfection methods, Tretinoin pharmacology, Calcium metabolism, Calcium Signaling physiology, Cell Nucleus metabolism, Cyclic AMP Response Element-Binding Protein metabolism, Neurons cytology
- Abstract
The mechanism by which physiological synaptic NMDA receptor activity promotes neuronal survival is not well understood. Here, we show that that an episode of synaptic activity can promote neuroprotection for a long time after that activity has ceased. This long-lasting or "late phase" of neuroprotection is dependent on nuclear calcium signaling and cAMP response element (CRE)-mediated gene expression. In contrast, neuroprotection evoked acutely by ongoing synaptic activity relies solely on the activation of the phosphatidylinositol 3-kinase/Akt pathway. This "acute phase" does not require nuclear calcium signaling and is independent of activation of the CRE-binding protein (CREB) family of transcription factors. Thus, activity-dependent neuroprotection comprises two mechanistically distinct phases that differ in their spatial requirements for calcium and in their reliance on the CREB family.
- Published
- 2005
- Full Text
- View/download PDF
8. Nuclear Ca2+ and CaM kinase IV specify hormonal- and Notch-responsiveness.
- Author
-
McKenzie GJ, Stevenson P, Ward G, Papadia S, Bading H, Chawla S, Privalsky M, and Hardingham GE
- Subjects
- 4-Aminopyridine pharmacology, Aniline Compounds metabolism, Animals, Bicuculline pharmacology, Calcium-Calmodulin-Dependent Protein Kinase Type 4, Cells, Cultured, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Diagnostic Imaging, Dose-Response Relationship, Drug, Drug Interactions, Enzyme Inhibitors pharmacology, Fluorescent Antibody Technique methods, GABA Antagonists pharmacology, Gene Expression Regulation drug effects, Green Fluorescent Proteins metabolism, Hippocampus cytology, Histone Deacetylases metabolism, Hydroxamic Acids pharmacology, Neurons drug effects, Neurons metabolism, Nuclear Receptor Co-Repressor 2, Okadaic Acid pharmacology, Potassium Channel Blockers pharmacology, Protein Synthesis Inhibitors pharmacology, Receptors, Notch, Receptors, Retinoic Acid metabolism, Receptors, Thyroid Hormone metabolism, Repressor Proteins genetics, Repressor Proteins metabolism, Signal Transduction, Time Factors, Transcription, Genetic, Transcriptional Activation, Transfection methods, Tretinoin pharmacology, Xanthenes metabolism, Calcium metabolism, Calcium-Calmodulin-Dependent Protein Kinases metabolism, Cell Nucleus metabolism, Hormones pharmacology, Membrane Proteins metabolism, Neurons cytology
- Abstract
Many neuronal processes require gene activation by synaptically evoked Ca(2+) transients. Ca(2+)-dependent signal pathways activate some transcription factors outright, but here we report that such signals also potentiate the activation of nuclear receptors by their cognate hormone, and of CBF1 by Notch, transcription factors hitherto not thought to be Ca(2+)-responsive. This potentiation is occluded by histone deacetylase inhibition, indicating a mechanism involving inactivation of co-repressors associated with these transcription factors. Synaptic activity, acting via the nuclear Ca(2+)-dependent activation of CaM kinase IV, triggers the disruption of subnuclear domains containing class II histone deacetylases (HDACs) and silencing mediator of retinoic acid and thyroid hormone receptors (SMRT), a broad-specificity co-repressor which represses nuclear hormone receptors and CBF1. The sequential loss of class II HDACs and SMRT from the subnuclear domains, followed by nuclear export, is associated with disruption of SMRT interaction with its target transcription factors and sensitization of these factors to their activating signal. Counterbalancing these changes, protein phosphatase 1 promotes nuclear localization of SMRT and inactivation of nuclear receptors and CBF1. Thus, the synaptically controlled kinase-phosphatase balance of the neuron determines the efficacy of SMRT-mediated repression and the signal-responsiveness of a variety of transcription factors.
- Published
- 2005
- Full Text
- View/download PDF
9. Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons
- Author
-
Fricker, Michael, Papadia, Sofia, Hardingham, Giles E., and Tolkovsky, Aviva M.
- Subjects
Cerebral Cortex ,Mice, Knockout ,Neurons ,Tumor Suppressor Proteins ,Nuclear Proteins ,Apoptosis ,Article ,Mice ,Animals, Newborn ,hemic and lymphatic diseases ,Nerve Degeneration ,Animals ,biological phenomena, cell phenomena, and immunity ,Tumor Suppressor Protein p53 ,Apoptosis Regulatory Proteins ,Signal Transduction - Abstract
Puma (p53 up-regulated modulator of apoptosis) is a BH3-only protein member of the Bcl-2 family that controls apoptosis by regulating the release of pro-apoptotic factors from mitochondria. Previously, we reported that sodium arsenite (NaAsO(2)) induces Puma-dependent apoptosis in cortical neurons in a p53-independent manner. The following evidence shows that p53-independent Puma activation by NaAsO(2) is mediated by the p53-related protein TAp73: (i) NaAsO(2) causes TAp73alpha accumulation and increases p53-independent expression of p73 target genes; (ii) two p53 response elements in the Puma promoter are required for NaAsO(2)-mediated activation of a Puma reporter construct; (iii) expression of the inhibitory DeltaNp73alpha and DeltaNp73beta isoforms decreases NaAsO(2)-mediated induction of Puma and other p53-family target genes in a p53-null background; (iv) DeltaNp73alpha and DeltaNp73beta expression protects the neurons from NaAsO(2)-dependent apoptosis. Interestingly, although ER stressors also induce p53-independent, Puma-dependent apoptosis, they do not increase TAp73 expression while NaAsO(2) does not induce notable endoplasmic reticulum (ER) stress. In contrast, DNA damaging agents, okadaic acid, and H(2)O(2) all induce apoptosis in a strictly Puma- and p53-dependent manner. Hence, the pivotal position of Puma as mediator of apoptosis in cortical neurons is because of the availability of at least three independent signalling pathways that ensure its activation.
- Published
- 2010
10. Neuronal activity controls the antagonistic between PGC-1α and SMRT in regulating antioxidant defences
- Author
-
Soriano Zaragoza, Francesc X. (Francesc Xavier), Léveillé, Frédéric, Papadia, Sofia, Bell, Karen F. S., Puddifoot, Clare, Hardingham, Giles E., and Universitat de Barcelona
- Subjects
Neurons ,Genetic regulation ,Corea de Huntington ,Malalties neurodegeneratives ,Regulació genètica ,Neurones ,Neurodegenerative Diseases ,Huntington's chorea - Abstract
Transcriptional coactivators and corepressors often have multiple targets and can have opposing actions on transcription and downstream physiological events. The coactivator peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α is under-expressed in Huntington's disease and is a regulator of antioxidant defenses and mitochondrial biogenesis. We show that in primary cortical neurons, expression of PGC-1α strongly promotes resistance to excitotoxic and oxidative stress in a cell autonomous manner, whereas knockdown increases sensitivity. In contrast, the transcriptional corepressor silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) specifically antagonizes PGC-1α-mediated antioxidant effects. The antagonistic balance between PGC-1α and SMRT is upset in favor of PGC-1α by synaptic activity. Synaptic activity triggers nuclear export of SMRT reliant on multiple regions of the protein. Concommitantly, synaptic activity post-translationally enhances the transactivating potential of PGC-1α in a p38-dependent manner, as well as upregulating cyclic-AMP response element binding protein-dependent PGC-1α transcription. Activity-dependent targeting of PGC-1α results in enhanced gene expression mediated by the thyroid hormone receptor, a prototypical transcription factor coactivated by PGC-1α and repressed by SMRT. As a consequence of these events, SMRT is unable to antagonize PGC-1α-mediated resistance to oxidative stress in synaptically active neurons. Thus, PGC-1α and SMRT are antagonistic regulators of neuronal vulnerability to oxidative stress. Further, this coactivatorcorepressor antagonism is regulated by the activity status of the cell, with implications for neuronal viability.
- Published
- 2010
11. Nuclear Ca2+ and CaM kinase IV specify hormonal- and Notch-responsiveness.
- Author
-
Mckenzie, Grahame J., Stevenson, Patrick, Ward, George, Papadia, Sofia, Bading, Hilmar, Chawla, Sangeeta, Privalsky, Martin, and Hardingham, Giles E.
- Subjects
PROTEIN kinases ,NEURONS ,CALCIUM ,MITOGENS ,TRANSCRIPTION factors ,HISTONE deacetylase ,NEUROCHEMISTRY - Abstract
Many neuronal processes require gene activation by synaptically evoked Ca
2+ transients. Ca2+ -dependent signal pathways activate some transcription factors outright, but here we report that such signals also potentiate the activation of nuclear receptors by their cognate hormone, and of CBF1 by Notch, transcription factors hitherto not thought to be Ca2+ -responsive. This potentiation is occluded by histone deacetylase inhibition, indicating a mechanism involving inactivation of co-repressors associated with these transcription factors. Synaptic activity, acting via the nuclear Ca2+ -dependent activation of CaM kinase IV, triggers the disruption of subnuclear domains containing class II histone deacetylases (HDACs) and silencing mediator of retinoic acid and thyroid hormone receptors (SMRT), a broad-specificity co-repressor which represses nuclear hormone receptors and CBF1. The sequential loss of class II HDACs and SMRT from the subnuclear domains, followed by nuclear export, is associated with disruption of SMRT interaction with its target transcription factors and sensitization of these factors to their activating signal. Counterbalancing these changes, protein phosphatase 1 promotes nuclear localization of SMRT and inactivation of nuclear receptors and CBF1. Thus, the synaptically controlled kinase-phosphatase balance of the neuron determines the efficacy of SMRT-mediated repression and the signal-responsiveness of a variety of transcription factors. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
12. Human Semaphorin 3 Variants Link Melanocortin Circuit Development and Energy Balance
- Author
-
Van Der Klaauw, AA, Croizier, S, De Oliveira, E, Stadler, LKJ, Park, S, Kong, Y, Banton, MC, Tandon, P, Hendricks, AE, Keogh, JM, Riley, SE, Papadia, S, Henning, E, Bounds, R, Bochukova, EG, Mistry, V, O'Rahilly, S, Simerly, RB, Interval, Consortium, Uk10K, Minchin, JEN, Barroso, I, Jones, EY, Bouret, SG, Farooqi, IS, University of Cambridge [UK] (CAM), Addenbrooke's Hospital, Cambridge University NHS Trust, University of Southern California (USC), Université de Lausanne = University of Lausanne (UNIL), University of Oxford, Pathogénèse des Infections vasculaires / Pathogenesis of Vascular Infections, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Plymouth University, University of Edinburgh, The Wellcome Trust Sanger Institute [Cambridge], University of Colorado [Denver], Queen Mary University of London (QMUL), Vanderbilt University [Nashville], Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Studies in humans were supported by Wellcome (AAvdK, IB, ISF, 099038/Z/12/Z, 098497/Z/12/Z, WT098051), the Medical Research Council (MRC) (ISF, SOR, MRC_MC_UU_12012/5), the National Institute of Health Research (NIHR), Cambridge Biomedical Research Centre (ISF, IB, SOR), and the Bernard Wolfe Health Neuroscience Endowment (ISF). E.M.d.O. was supported by the Brazilian National Council for Scientific and Technological Development- CNPq (233690/2014-0). J.E.N.M. was supported by a joint University of Edinburgh and British Heart Foundation (BHF) Centre of Research Excellence Fellowship. S.G.B. was supported by the NIH (DK84142, DK102780, and DK118401). Structural analysis was performed by Y.K. and E.Y.J., who are supported by Cancer Research UK and the UK MRC (C375/A17721 and MR/M000141/1 to E.Y.J.) and Wellcome (203141/Z/16/Z, supporting the Wellcome Centre for Human Genetics). Whole-exome sequencing was performed as part of the UK10K consortium (a full list of investigators who contributed to the generation of the data is available from https://www.uk10k.org/). Participants in the INTERVAL randomized controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (https://www.nhsbt.nhs.uk/), which has supported field work and other elements of the trial. DNA extraction and genotyping was co-funded by the NIHR, the NIHR BioResource (https://bioresource.nihr.ac.uk/), and the NIHR Cambridge Biomedical Research Centre (www.cambridgebrc.nihr.org.uk/). The academic coordinating center for INTERVAL was supported by core funding from the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK MRC (MR/L003120/1), BHF (RG/13/13/30194), and NIHR Cambridge BRC. A complete list of the investigators and contributors to the INTERVAL trial is provided (Moore et al., 2014)., CCSD, Accord Elsevier, Université de Lausanne (UNIL), University of Oxford [Oxford], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), van der Klaauw, Agatha [0000-0001-6971-8828], Stadler, Lukas [0000-0002-7028-4390], Papadia, Sofia [0000-0002-9222-3812], O'Rahilly, Stephen [0000-0003-2199-4449], Barroso, Ines [0000-0001-5800-4520], Farooqi, Ismaa [0000-0001-7609-3504], Apollo - University of Cambridge Repository, INTERVAL, and UK10K Consortium
- Subjects
Adult ,Leptin ,Male ,Plexins ,obesity ,Adolescent ,[SDV]Life Sciences [q-bio] ,Pomc ,Nerve Tissue Proteins ,Receptors, Cell Surface ,Semaphorins ,Article ,Cell Line ,Eating ,Mice ,Young Adult ,Animals ,Body Weight ,Child ,Child, Preschool ,Disease Models, Animal ,Energy Metabolism/genetics ,Female ,Genetic Variation/genetics ,Homeostasis ,Humans ,Hypothalamus/metabolism ,Leptin/metabolism ,Melanocortins/metabolism ,Mice, Inbred C57BL ,Middle Aged ,Nerve Tissue Proteins/metabolism ,Neurons/metabolism ,Obesity/genetics ,Obesity/metabolism ,Receptors, Cell Surface/metabolism ,Semaphorins/genetics ,Semaphorins/metabolism ,Zebrafish ,AgRP ,Neuropilins ,Semaphorin 3s ,hypothalamus ,Neurons ,Genetic Variation ,Melanocortins ,[SDV] Life Sciences [q-bio] ,nervous system ,Energy Metabolism - Abstract
Summary Hypothalamic melanocortin neurons play a pivotal role in weight regulation. Here, we examined the contribution of Semaphorin 3 (SEMA3) signaling to the development of these circuits. In genetic studies, we found 40 rare variants in SEMA3A-G and their receptors (PLXNA1-4; NRP1-2) in 573 severely obese individuals; variants disrupted secretion and/or signaling through multiple molecular mechanisms. Rare variants in this set of genes were significantly enriched in 982 severely obese cases compared to 4,449 controls. In a zebrafish mutagenesis screen, deletion of 7 genes in this pathway led to increased somatic growth and/or adiposity demonstrating that disruption of Semaphorin 3 signaling perturbs energy homeostasis. In mice, deletion of the Neuropilin-2 receptor in Pro-opiomelanocortin neurons disrupted their projections from the arcuate to the paraventricular nucleus, reduced energy expenditure, and caused weight gain. Cumulatively, these studies demonstrate that SEMA3-mediated signaling drives the development of hypothalamic melanocortin circuits involved in energy homeostasis., Graphical Abstract, Highlights • Rare variants affecting Semaphorin 3 signaling are associated with human obesity • Disruption of Semaphorin 3 signaling leads to weight gain in zebrafish and mice • Semaphorin 3 signaling promotes the development of hypothalamic melanocortin circuits, Semaphorin 3 signaling promotes the development of hypothalamic circuits, and human variants are associated with obesity.
- Published
- 2019
- Full Text
- View/download PDF
13. SynGAP isoforms exert opposing effects on synaptic strength
- Author
-
Aoife McMahon, Jyoti S. Choudhary, Mark W. Barnett, Giles E. Hardingham, Noboru H. Komiyama, Timothy O'Leary, Sofia Papadia, Peter C. Kind, David J. A. Wyllie, P N Stoney, Mark O. Collins, Seth G. N. Grant, O'Leary, Timothy [0000-0002-1029-0158], Papadia, Sofia [0000-0002-9222-3812], and Apollo - University of Cambridge Repository
- Subjects
Gene isoform ,Chemistry(all) ,Molecular Sequence Data ,General Physics and Astronomy ,Physics and Astronomy(all) ,Biology ,SYNGAP1 ,Hippocampus ,Mass Spectrometry ,Article ,General Biochemistry, Genetics and Molecular Biology ,Primer extension ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Rapid amplification of cDNA ends ,Animals ,Protein Isoforms ,Amino Acid Sequence ,Peptide sequence ,030304 developmental biology ,Neurons ,Genetics ,0303 health sciences ,Multidisciplinary ,Biochemistry, Genetics and Molecular Biology(all) ,Alternative splicing ,General Chemistry ,Cell biology ,Electrophysiology ,Mice, Inbred C57BL ,ras GTPase-Activating Proteins ,Synapses ,Synaptic plasticity ,Excitatory postsynaptic potential ,030217 neurology & neurosurgery - Abstract
Alternative promoter usage and alternative splicing enable diversification of the transcriptome. Here we demonstrate that the function of Synaptic GTPase-Activating Protein (SynGAP), a key synaptic protein, is determined by the combination of its amino-terminal sequence with its carboxy-terminal sequence. 5′ rapid amplification of cDNA ends and primer extension show that different N-terminal protein sequences arise through alternative promoter usage that are regulated by synaptic activity and postnatal age. Heterogeneity in C-terminal protein sequence arises through alternative splicing. Overexpression of SynGAP α1 versus α2 C-termini-containing proteins in hippocampal neurons has opposing effects on synaptic strength, decreasing and increasing miniature excitatory synaptic currents amplitude/frequency, respectively. The magnitude of this C-terminal-dependent effect is modulated by the N-terminal peptide sequence. This is the first demonstration that activity-dependent alternative promoter usage can change the function of a synaptic protein at excitatory synapses. Furthermore, the direction and degree of synaptic modulation exerted by different protein isoforms from a single gene locus is dependent on the combination of differential promoter usage and alternative splicing., Synaptic GTPase-activating protein, SynGAP, is a postsynaptic signalling protein that can regulate synaptic function. McMahon et al. express different SynGAP isoforms in neurons and find that the effect on synaptic strength depends on alternative promoter usage and alternative splicing of the C-terminus.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.